Do you need in-depth information?

You will find detailed information of our possibilities in our downloadable brochures:

Open download page!

Novel Immuotherapeutics

Over the last few years Pharmedartis has in collaboration with the Fraunhofer IME (PPD group) intensively worked on the development, construction, expression and characterization of recombinant immunotherapeutics.

Recombinant immunotoxins

are a well-established concept for the treatment of e. g. cancer

read more

Apoptotic agents

such as proteases or RNases are key elements for our immunotherapeutic developments.

read more


and others are the basis of a highly innovative threatment strategy first developed by one of our founder.

read more